Flex Pharma Inc  

(Public, NASDAQ:FLKS)   Watch this stock  
Find more results for ELIZABETH HAHN´┐Ż
-0.03 (-0.42%)
Real-time:   2:00PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.00 - 7.56
52 week 6.92 - 24.82
Open 7.06
Vol / Avg. 25,852.00/93,919.00
Mkt cap 112.45M
P/E     -
Div/yield     -
EPS -1.78
Shares 17.94M
Beta     -
Inst. own 56%
Mar 15, 2016
Q4 2015 Flex Pharma Inc Earnings Release (Estimated) Add to calendar
Feb 2, 2016
Flex Pharma, Inc. Announces Positive Human Efficacy in Nocturnal Leg Cramp Study - Conference Call - Webcast
Dec 8, 2015
Flex Pharma Inc at Oppenheimer Healthcare Conference
Dec 1, 2015
Flex Pharma Inc at Piper Jaffray 27th Annual Healthcare Conference - Webcast
Nov 19, 2015
Flex Pharma Inc at the Jefferies Autumn Global Healthcare Conference - Webcast
Nov 17, 2015
Flex Pharma Inc at the Stifel Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -31.45% -
Return on average equity -32.27% -
Employees 19 -
CDP Score - -


800 Boylston St Fl 24
BOSTON, MA 02199-8119
United States - Map
+1-617-8741821 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Flex Pharma, Inc. is a biotechnology company that is developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms for neuromuscular conditions. The Company focuses its drug development efforts on developing a product to treat nocturnal leg cramps. The Company's treatment, which forms the basis of both drug product and consumer product development efforts, activates the transient receptor potential (TRP) cation channel receptors in primary sensory neurons in the spinal cord that enhances overall inhibitory tone in motor neurons throughout the body. The Company's pre-clinical drug product candidates are offered for Nocturnal leg cramps, and MS spasticity, cervical dystonia and/or SCI spasticity. The Company's consumer brand and products focuses athletes experiencing exercise-associated muscle cramps, or EAMCs. The Company has commenced formulation and commercialization efforts of its consumer brand.

Officers and directors

Christoph H. Westphal Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 46
Bio & Compensation  - Reuters
Marina Hahn President, Consumer
Age: 57
Bio & Compensation  - Reuters
Kathie Lindemann Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
John McCabe Vice President - Finance, Treasurer
Age: 45
Bio & Compensation  - Reuters
Jennifer Cermak Ph.D. Vice President - Research & Development
Age: 42
Bio & Compensation  - Reuters
Robert Hadfield Ph.D. General Counsel, Secretary
Age: 37
Bio & Compensation  - Reuters
Elizabeth Woo M.D., Ph.D. Senior Vice President, Investor Relations and Corporate Communications
Age: 48
Bio & Compensation  - Reuters
Thomas C. Wessel M.D., Ph.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Jeffrey D. Capello Director
Age: 50
Bio & Compensation  - Reuters
Roderick Mackinnon M.D Director
Age: 59
Bio & Compensation  - Reuters